Moderna Entered into a Collaboration and License Agreement with Cytomx to Develop mRNA-Based Conditionally Activated Therapies
Shots:
- CytomX to receive $35M up front incl. $5M in pre-paid research funding, ~$1.2B in development, regulatory, & commercial milestones along with royalties on global net sales of any products
- Both companies will work closely on the early stages of development, incl. drug discovery & pre-clinical assessments. Moderna will also retain an option to participate in equity financing (conducted by CytomX) in the future & lead the clinical development & commercialization of therapies
- The collaboration will combine Moderna's mRNA technologies & CytomX's Probody therapeutic platform to develop mRNA-based conditionally activated therapies for oncology & non-oncology conditions
Ref: MODERNA | Image: MODERNA
Related News:- Pfizer and BioNTech Initiate P-I Study of mRNA-Based Combination Vaccine for the Treatment of COVID-19 and Influenza
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
